Compare Main Street Capital Corporation (MAIN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Neurocrine Biosciences Inc — how do they compare? Main Street Capital Corporation trades at $58.84 (market cap $5.47B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.1× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.43% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MAIN | NBIX | |
|---|---|---|
Market Cap | $5.47B | $16.76B |
Sector | Financials | Health |
52-Week High | $67.54 | $185.50 |
52-Week Low | $49.63 | $123.10 |
Dividend Yield | 5.43% | — |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $58.94, up 3.79% with strong technical momentum. The stock shows bullish technical signals with support at $57 and resistance at $60. Recent Q2 2026 earnings beat expectations at $0.97 per share, though Q1 missed. The company maintains an 80.77% net income margin with consistent dividend payments, positioning it as a reliable income stock. Revenue trends show slight moderation from 2024's peak but remain above 2022-2023 levels.
Outlook remains positive given MAIN's strong profitability and dividend consistency, though near-term risks include expense pressures impacting earnings coverage and broader market volatility. Analyst consensus leans cautious with 78.57% hold ratings, suggesting limited upside from current levels despite the stock's technical strength and income appeal.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
